Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Tobin

Plastic Surgery Cape Girardeau, MO Medical Doctor

NPI 1821097239 CMS profile 956121

300 S Mount Auburn Rd, Ste 100, Cape Girardeau, MO 63703

Open in the dashboard

General payments

$185

11 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Tobin of Cape Girardeau, MO is reported in the CMS Open Payments database as having received $185 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 13th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $62 2
2024 General $39 3
2023 General $13 1
2022 General $19 1
2021 General $40 3
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Tobin
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Gregory Tobin were reported at $62. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Gregory Tobin Plastic Surgery median Middle half National median
2019 $12 $371 $122–$1,483 $163
2020 $0 $158 $52–$438 $114
2021 $40 $249 $87–$752 $132
2022 $19 $274 $102–$793 $149
2023 $13 $299 $113–$891 $160
2024 $39 $361 $124–$1,062 $164
2025 $62 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $79 6 payments
  2. Galderma Laboratories, L.P. $53 3 payments
  3. PolyNovo North America LLC $41 1 payment
  4. Elite Orthopedics, LLC $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $185 11 payments
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $68 5 payments
  2. ARTOURA Breast Tissue Expander Plastic Surgery $52 4 payments
  3. NOVOSORB BTM $41 1 payment
  4. FlexHD Acellular Hydrated Dermis $12 1 payment
  5. MemoryGel Breast Implants $12 1 payment
  6. ARTOURA Breast Tissue Expander Plastic Surgery $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

261

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$1,204

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

54%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 96 $660
Cephalexin Generic 106 $255
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 24 $127
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $111
Azithromycin Generic 14 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 127 billing codes

Paid by Medicare

$88,281

Of which drugs: $37

Medicare patients

193

Average age 74

Services billed

747

114 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 55%
Diabetes 26%
Ischemic heart disease 19%
COPD 17%
Depression 16%
Osteoporosis 13%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 48 $33
Injection, lidocaine hcl for intravenous infusion, 10 mg J2001 Office 22 33 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record